LESSON 1- 090519

Welcome to "APPLICATIONS IN MEDICINE", module of Advanced Molecular Biology.

I am CUTRUPI SANTINA, professor in Molecular biology. My research field is the role of estrogen receptor (ER) in the immune systems. The immune systems play a crucial role to defense organisms against pathogens. However, the immune systems dysregulation is involved in autoimmune disease (AD), such as Multiple Sclerosis. In our lab, we are studying how ER can act as immunomodulatory factors in the AD.

The topic of this module is how the biomolecular approach is used to understand disease. However, the goal of this module is to develop specific expertise in molecular biology.

The skills that the course wants to develop are:

PROBLEM SOLVING in the application of molecular biology IN MEDICINE

EXPERIMENTAL DESIGN to understand molecular mechanisms linked to disease

How can we improve these skills?

- Papers analysis
- Design experiments.

The lesson structure is composed from one part to explain main concepts and the other part with quiz.

We'll use a "TRAINING TASK".

What is the meaning of this approach?

- Help you to understand the main concept in the deep way
- Help you to REMEMBER the main concept
- Help you to apply the main concept to solve problem

No "classic" evaluation using number, but I'll use a comment that help you to understand the mistake and improve learning.

The goal is your learning, so stop me if you don't understand or want to explain one topic in more details. You can send me email, too.

In this lesson, we'll discuss about:

- What is the main focus of the course
- Definition of Functional Genomics
- How Functional Genomics is the basis for understanding diseases
- Integration Data
- Application of Functional Genomics and Integration Data

We'll start with a quiz on the Moodle platform.

Activity 1: what is Functional Genomics. Search by google. Compare your definition with the proposal of teacher.

The main focus of this course is **FUNCTIONAL GENOMICS**. This research field has an important impact in the comprehension of the molecular mechanism underpinning disease and open the way to biomarkers identification and drug discovery.

What is the meaning of "functional genomics"?

Functional genomics uses genomic data to study gene expression, regulation and biological functions on a global scale (genome-wide or system-wide), focusing on gene transcription, epigenetic modifications, chromatin remodelling enzymes, transcription factors association involving high-throughput methods.

In the body there are many types of cells, such as neuron, muscle cell, lymphocytes and so on. Each cell has the same genome, but transcribes different sets of genes, leading to differences in the character and function. In different cells, or in the same cell at different times, a sets of genes might be transcribed.

One main focus of functional genomics is the identification of genomic regulatory regions that form the core regulatory network together with transcriptions factors.

The genomic regulatory regions that are used from the cells control gene expression. The genes pattern expressed from the cells defines cell identity and biological functions. the genomic regulatory regions are defined by:

- EPIGENETIC MARKS

- TRANSCRIPTION FACTORS BINDING

- CHROMATIN REMODELLING ENZYMES
- NUCLEOSOME POSITIONING

- Functional genomics uses genome-wide data to annotate genome sequence.

An ongoing challenge in biology is comprehensively mapping genotype-phenotype relationships. With this objective in mind, functional genomics makes use of data from all levels of biology (genome, transcriptome, epigenome, proteome, metabolome, etc.) to better define genetic and protein functions and interactions. In this way, researching functional genomics is essential for better understanding the human genome and its intricate interactions in healthy, as well as pathophysiologic states. Characterizing the functional consequences of genomic variation is crucial for some aspects of biomedical research including cancer screening methodologies, drug-drug interactions, drug sensitivity and resistance, gene therapy, regenerative medicine applications, infectious disease, and general understanding of human physiology.

- For example, the analysis of tumors sample can include: one hand, DNA sequencing of patients or trascriptomics and proteomics that can help us to identify the difference with healthy people. The role of the mutation in single nucleotide variants or gene expression or type of proteins can be tested in cell models using specific tests.
- The future perspective is that the results derived from functional tests could be used to select drug efficacy for that patient.
- In order to understand the role of specific genome sequence we can use several functional assay, included CRISPR-Cas9 system.
- CRISPR-Cas9 system.
- Genome wide- approach can be used in functional tests. One example of functional test is the application of CRISPR-Cas9 system. CRISPR-Cas9 system is used to modify the genome and you can delete or substitute specific genomic regions. Deletion of genomic region can have an impact on cell proliferation or survival or change gene expression.
- CRISPR-Cas9 is a system based on the recognition of specific genomic region by RNA guide that form a complex with Cas9, nuclease. Cas9 can cut DNA sequence and this sequence can be deleted or can be insert another sequence, so we substitute one sequence with another sequence. In these example there are the use of virus infection to add a plasmid that contains the sequence for RNAg. Edited cells can be used in several assays.

Functional tests in Functional Genomics.

- In this picture, we can see several experimental assay. Leukemia cells derived from patients can be analyzed under different aspects to attribute function to specific proteins or transcripts or genomic regulatory regions.

- In this picture you can look at the reconstruction of genomic regulatory regions. We can find promoter and enhancer. There are RNA polymerase, TFs, cofactors that form a transcriptional complex. When the transcriptional complex is active, we have gene transcription with RNA transcript synthesis.
- We saw the several tracks that indicate signal enrichment and profile associated with different data. The comparison of several data is a visualization approach that represents a simple example of integration data.

What is the meaning of "integration data"?

Integration data is a computational tool to use data that derived from different genome-wide sequencing. This is very complex analysis, but I want to show you another manner to use integrative approach.

comparison between several types of genome-wide data that involved the algorithm development.

Advances in omics technologies — such as genomics, transcriptomics, proteomics and metabolomics — have begun to enable personalized medicine at an extraordinarily detailed molecular level. Individually, these technologies have contributed medical advances that have begun to enter clinical practice. However, each technology individually cannot capture the entire biological complexity of most human diseases. Integration of multiple technologies has emerged as an approach to provide a more comprehensive view of biology and disease. Data integration is an approach to identify biomarkers or discover a regulatory network that underpinned the regulation of cell identity and function.

Genomics and transcriptomics are linked with functional genomics. Genome- wide data sequencing is used to give a meaning to DNA sequences or RNA transcripts.

- Integration data approach consists of visualization on Genome Browsers and development of algorithms. We don't discuss about algorithms discovery, but we can find them in the articles.

In this picture there is the illustration of the basic concept for data integration. Several data are integrated to identify the mechanism underpinning disease.

Recently, integration approach is used to describe neurological disorder. The hierarchical steps are shown and are applied to find regulatory networks. We can see several type of data.

- Raw data represents the collection of data that derived from NGS.
- The raw data are compared one to another to compare several types of cells and associate the variation of expression to single nucleotide variants that is linked with disease.
- The integration approach reveals the relationships between different genes or proteins and reconstruct the interconnection: interaction between two proteins or identification which are the targets of a TF.

- These analyses are complex however this view summarized how genome-wide data can be used and different types of analysis and visualization.

One alteration in the genomic regulatory regions, such as enhancer, may induce transcription activation of the gene that play a role in the disease. So, activation of enhancer respect healthy state can induce pathological conditions.

The alteration in the enhancer may be single nucleotide variants.

Types of SNPs, that can play a role in the disease, can be associated with non coding sequence, linked to genomic regulatory regions, or coding sequence, linked to protein structure and function.

What types of alterations in the molecular mechanism could induce diseases:

- Single nucleotide variations into the genomic regulatory regions change the consensus sequences for transcription factors binding
- Single nucleotide variations into the genomic regulatory regions change long range interactions between two regulatory regions
- Single nucleotide variations into the coding sequence of proteins change:
- a) Enzimatic activity
- b) Protein-protein interactions
- c) Cofactors binding

In this view, there is the description of the possible function of SNPs in the genomic regulatory regions. The SNPs can change the enhancer activation and, for example, induce the activation of gene C expression. During the course, we will describe in more details the role of SNPs in the disease. We focus attention on one genomic regions, however we can extend this view for all genome.

The studies that have indentified the SNPs linked to specific disease are called GWAS (Genome-wide association studies).

How functional genomics is a tool to understand disease

In order to show an overview of research plan for studying the role of SNPs I will present an example.

In this number of Neuroscience there is a description of the meaning of SNPs linked to psychiatric diseases.

A SNP may change the molecular mechanisms that control gene expression, such as TFs association with chromatin.

Which are the steps to understand the SNPs meaning?

The first step is the sequencing of patients genome. The comparison of the genome sequences between healthy and patients show the nucleotide variations. The SNPs associated with disease are collected in GWAS database. The next steps are: functional annotation, experimental validation in vitro, using cellular or disease animal models.

The second step to understand whether SNP has a role in disease outcome is FUNCTIONAL ANNOTATION. For localization of the SNP in the specific genomic regions we can used genome wide data.

FUNCTIONAL ANNOTATION is the method used to search whether SNPs are associated with specific genomic regions and which are the features of these regions, such as transcription factors association, epigenetic modifications and others. In order to describe SNP-associated regions we can used genome-wide sequencing data. Therefore, SNPs may be associated with a genomic regions described as enhancers, promoter, silencer or repressor regions. These information permit us to formulate hypothesis about SNP function, for example SNP in the genomic regulatory region may change the expression of nearest gene.

SNPs in the genomic region may alter a binding site of a specific TFs, such as PU.1 and chromatin states change in the same region

The genome Reference (Ref) is compare with the genome "Altered" (Alt) (SNPs). We observed the analysis of several aspects in the enhancer region, Tatem-VCM: PU.1 binding, histone modifications and PolII binding. In Ref sample, we find a peak that corresponds with the PU.1 binding, while a low signal is associated with Alt sample. In the gene body, we find an high signal of PolII binding and PU.1 in the vcmQTL regions in the Alt sample suggesting that the alteration in the genomic regulatory regions induced PU.1 binding and this SNP is linked with gene transcription.

Why?

Is a variant regulatory?

If we found a change in the signal of peak we can suppose that this variant changes the transcription binding sites. The specific algoritm indicates whether this variant impairs the transcription factor binding.

In enhancer, several TFs form a regulatory complex that control gene expression, but the variant in one TF binding site can impair the formation of regulatory complexes. This alteration can change the cell fate and define the disease trait.

Distinct Modes of Genetic Variation-Mediated Changes in TF-DNA Binding

(A) Only a minority of variable TF-DNA binding events are caused by DNA variants disrupting the cognate TF recognition motif. (B-D) The majority of variably binding events are motif variation independent, indicating that a variant located either proximally (<200 bp,Band C) or distally (D) to the focal motif affects the binding of the respective TF. Proximal variants can affect local cooperative DNA binding (B), which involves physical proteinprotein interactions that require overlapping or very closely located (a few bp) motifs, or collaborative DNA binding (C), which reflects TF interdependencies needed, for example, to compete with nucleosomes and thus to access DNA. In contrast, distal variants (D) may alter chromatin state or conformation (e.g., DNA loops), which could affect the stability of interactions with DNA and between TFs.

Using animal or cell lines models we can verify the functions of SNPs. For example, the preclinical disease model could be a transgenic mice with mutation in the genomic regulatory regions that correspond with SNP of interest. Several levels of studies can be applied: DNA, RNA (look at the diapo), Behavior and Cognition tests.

Another example for identification of SNP role is the tumorigenesis.

The pipeline to investigate SNP is the same that is describe for neurological disorder.

- 1) Sequencing the genome and select the SNPs associated with disease
- 2) Functional annotation using bioinformatic tool that help us to localize SNP in a specific genomic regions and to know the information about that genomic locus.

Experimental validation:

Mutations in cloned DNA fragments can be generated using **site-directed mutagenesis** or the **CRISPR–Cas system**. **Synthetic oligonucleotides** with a wild-type or mutant sequence can also be chemically synthesized. **b** | Functional output of the non-coding mutations can be determined either using a single or combinatorial approach involving high-throughput sequencing and/or luciferase (LUC) reporter assays. **In high-throughput sequencing**, effects of mutations in *cis*-regulatory elements (promoters and enhancers) can be studied by an approach called *cis*-regulatory element analysis by sequencing (CRE-seq)_{118,122}. For **CRE-seq**, synthetic regulatory element constructs with wild-type and mutated sequence are cloned into reporter construct, which is tagged at the 3' end using a specific nucleotide barcode that identifies the upstream promoter or enhancer element. In **an alternative method** for characterizing enhancer variants, self-transcribing active regulatory region sequencing. **(STARR-seq**)₁₁₉, enhancer libraries are flanked by synthetic adaptor DNA sequences and cloned downstream of a transcription reporter construct. For both approaches, RNA transcripts from these libraries are used for cDNA synthesis followed by high-throughput sequencing. The expression driven by each element is measured by the ratio of the fraction of reads in the cDNA pool and the genomic DNA pool for each library construct; the particular element driving the expression of each transcript is identified based on the sequence of the transcribed barcode (for CRE-seq) or the transcribed enhancer (for STARR-seq). This enables accurate quantification of the reporter transcript as a direct measure of the regulatory element activity. For the **LUC reporter assays**, DNA fragments cloned into the reporter vectors are transfected in cells followed by measuring the reporter activity. **c** | Oncogenic properties, such as cell proliferation, migration and invasion, can be tested *in vitro* using cell lines, and tumorigenesis can also be tested *in vivo* using model organisms.

Also in tumorigenesis there are association with clinical profile. SNPs meaning is the basis for application as biomarkers or to develop new drug.

SNPs role.

SNP has a gain of function when creates a consensus sequence for TF binding, therefore transcription is active.

SNP has a loss of function when disrupts a consensus sequence for TF binding, therefore transcription is repressed.

SNP may have a role in the affinity of TF binding, so when hormone concentration is low TF does not bind the regulatory regions and transcription is impaired.

In gene locus, for example IL2RA, there are several data of RNA-Seq, Histone Acetylation and cell-type specific TFs binding. In the upper part, there are disease-associated SNPs. For autoimmune disease, high number of SNPs linked to IL2RA, receptor for IL2, suggests autoimmune susceptibility.

The SNPs function could be tested in patients and we will find the correlation with clinical profile. How can we use these knowledge? SNPs-associated molecular mechanisms could be the basis for drug discovery or biomarkers. Biomarkers are the tools to follow disease outcome, while the molecular mechanisms that are involved in the disease help us for the identification of the target for a new drug.

All materials for the course are present in the web site. You will find the slides presentation, reviews and articles. In addition, you will find lesson audio and lesson notes that help you to mark the main concepts.

Final exam is a test composed of different types of questions: multiple choice, finding associations between phrases and two open questions.